The benefit of aspirin
in reducing cardiovascular (CV) events or mortality in those patients with
known CV disease (secondary prevention) is well established. However, the benefit of aspirin in those
without CV disease (primary prevention) is less clear. Various organizations have differing opinions
and recommendations regarding who, if anyone, should receive aspirin in this
capacity, and their recommendations are summarized further below. To go straight to the current recommendations, skip down to 'Current Recommendations'.
